Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Five Prime Therapeutics Inc.

www.fiveprime.com

Latest From Five Prime Therapeutics Inc.

Nektar's IL-2 Impresses In Combination With Bristol's Opdivo

Nektar's IL-2 stimulating agonist NKTR-214 combines well with Bristol's Opdivo in Phase I PIVOT-02 study presented at SITC meeting in November.

ImmunoOncology Cancer

Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.

ImmunoOncology Clinical Trials

Five Prime Bounces Back With Good Spin On Cabiralizumab Data

Bristol's new Phase I study of Opdivo with Five Prime's cabiralizumab in second-line pancreatic cancer restored faith in the combo for some investors, as did a full presentation of pancreatic cancer data slated for SITC.

Cancer ImmunoOncology

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • FivePrime Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Five Prime Therapeutics Inc.
  • Senior Management
  • Lewis T Williams, MD, PhD, Pres. & CEO
    Marc Belsky, SVP, CFO
    Aron Knickerbocker, COO
    Francis Sarena, Chief Strategy Officer
    Helen Collins, MD, SVP, CMO
  • Contact Info
  • Five Prime Therapeutics Inc.
    Phone: (415) 365-5600
    2 Corporate Dr.
    San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register